Clinical profile of patients with peripheral artery disease treated with high-pressure intermittent pneumatic compression in st. lukes medical center-quezon city: a 6-year retrospective cohort study

Abstract

Background: High-pressure intermittent pneumatic compression (HPIPC) has been proposed as an alternative intervention to supervised exercise to improve intermittent claudication in patients with peripheral artery disease (PAD). This intervention has already been introduced in the Philippines. However, no local data has been published regarding the clinical profile of patients with PAD treated with HPIPC. This study aims to determine the clinical profile of patients with PAD treated with HPIPC in St. Luke's Medical Center - Quezon City (SLMC-QC) from March 2015 to March 2021. Methods: A total of eighty-three (N = 83) adult patients aged ≥ 19 years with confirmed diagnosis of PAD and symptoms of intermittent claudication who received at least 12 sessions of HPIPC in the Department of Vascular Medicine of SLMC-QC from March 2015 to March 2021 were included in this retrospective cohort study. The primary outcome was identification of the clinical profile of the study population. Descriptive statistics were generated for all variables. Continuous variables were presented as mean standard deviation (SD). Nominal data were reported as frequencies and percentages. All data were analyzed using Statistical Package for the Social Sciences (SPSS) v27 software. Results: The mean (SD) age of the study population was 75 (14) years. Approximately 76% of them were aged ≥ 65 years (n = 63). Overall, there were more males (57%) than females (43%) in the study. Majority of the study population never smoked (70%), had hypertension (89%), diabetes (81%), dyslipidemia (78%) and abnormal ankle-brachial index (ABI, 80%). The mean (SD) ABI of the study population was 0.92 (0.5). Hemodynamically significant stenosis in the distal and proximal arterial segments of the lower extremities were 92% and 62% respectively. Conclusion: Age ≥ 65 years, male sex, never-smoker, hypertension, diabetes, and dyslipidemia define the clinical profile of patients with PAD treated with HPIPC in SLMC-QC from March 2015 to March 2021. Further studies are recommended to test the association of these risk factors to PAD and to determine the efficacy of HPIPC in the treatment of PAD..